Clinical Trial

The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies

Study acronym: PACMAN
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
PACMAN is a phase I/II single arm, open-label, multi-center study evaluating the safety of human CD19 CAR-T (huCAR19) produced locally using the Miltenyi Prodigy in children, adolescents and young adults with relapsed/refractory CD19+ hematological malignancies for whom no standard of care treatment is available.
Trial Details
NCT Number NCT07020260
Lead Sponsor Princess Maxima Center for Pediatric Oncology
Collaborators: Dutch Cancer Society, Miltenyi Biomedicine GmbH, University Medical Center Utrecht (UMCU)
Conditions Leukemia, Lymphoma
Enrollment 18 participants
Start Date 2025-09-01
Primary Completion 2027-09-01 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-13